摘要
可利霉素属于16元环大环内酯类抗生素,由多种酰化螺旋霉素组成,以3种异戊酰化螺旋霉素为主组分,在遗传改造后的螺旋链霉菌中发酵产生。它已经被国家药品监督管理局批准为国家一类新药,主要用于治疗上呼吸道感染。可利霉素除了具有抗细菌感染作用以外,还发现它具有多种药理活性如抗肿瘤、抗肝纤维化、抗炎、免疫调节等作用。最近研究还证实可利霉素还具有抗病毒活性,特别是对新冠病毒(SARS-CoV-2)也有良好的抑制活性,并在临床试验中证实对新冠肺炎患者具有一定疗效。阐明这些非抗菌的生物活性机制对扩宽可利霉素的适应症具有重要意义。
Carrimycin,a 16-membered macrolide antibiotic,is a group of 4"-acylated spiramycins with three 4"-O-isovalerylspiramycins as its major components,produced by recombinant Streptomyces spiramyceticus.It was a classⅠnew drug approved by National Medical Products Administration of China for the treatment of upper respiratory infections.Further studies demonstrated that carrimycin,besides its potent anti-bacterial activity,had a variety of other pharmacological activities,such as anti-tumor,anti-liver fibrosis,anti-aging,immunomodulatory and other effects.Recent data confirmed that carrimycin displayed strong inhibition against coronavirus and SARSCoV-2 in vitro,and also effective in anti-COVID19 clinical trials.Elucidation of these non-antimicrobial bioactivity mechanisms is of great significance for broadening the indication of carrimycin.
作者
夏明钰
赵小峰
谷普庆
王以光
赫卫清
Xia Ming-yu;Zhao Xiao-feng;Gu Pu-qing;Wang Yi-guang;He Wei-qing(Shenyang Pharmaceutical University,Shenyang 110016;Shen Yang Tonglian Group Co.,Ltd.,Shenyang 110042;Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences,Beijing 100050)
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2023年第6期610-616,共7页
Chinese Journal of Antibiotics
基金
国家自然科学基金(No.82073900)。
关键词
可利霉素
大环内酯类抗生素
药理活性
Carrimycin
Macrolide antibiotic(MA)
Pharmacological activity
作者简介
夏明钰,女,生于1975年,博士,副教授,研究方向:肿瘤药理学,E-mail:xmywd@vip.sina.com;通讯作者:赫卫清,E-mail:heweiqing@imb.pumc.edu.cn。
